Interactive Session - Society for Assisted Reproductive Technology - PGD: The How and When

Presenters

PGD: The How and When

Needs Assessment and Description
Embryo preimplantation genetic testing includes preimplantation genetic screening (PGS) for aneuploidy inversions. This live session will review all preimplantation genetic technologies available today and discuss in which clinical situations the use of these technologies is and is not appropriate. The application of this technology, the stage of embryo biopsy, whether one should perform a fresh embryo transfer or a frozen/thaw cycle, the limitations of this genetic technology, and how the results can be interpreted and applied to patient care will be discussed. The goal of this interactive session will be to open a dialogue about the advantages and disadvantages of the varied strategic approaches to offer preimplantation genetic testing. This topic should have value for all members of in vitro fertilization (IVF) programs considering or offering preimplantation genetic testing to their patients.

Learning Objectives
At the conclusion of this session, participants should be able to: 

1. Identify the current strategies for PGD, including the best stage for biopsy. 
2. Describe the limitations of current technologies. 
3. Discuss the future direction of these technologies.

ACGME Competency
Medical Knowledge

TEST QUESTION:
Recent data document that approximately 65-70% of all first trimester miscarriages are aneuploid. After participating in this session, in my practice, for a couple undergoing IVF with PGS, the following preimplantation genetic test would be least appropriate: 

1. Single-nucleotide polymorphism microarray for all chromosome pairs 
2. Low-density comparative genomic hybridization microarray for all chromosome pairs 
3. Quantitative real time polymerase chain reaction for all chromosome pairs 
4. 10-12 probe fluorescence in situ hybridization 
5. Not applicable to my area of practice